- Home
- MRSN vs ICG Comparison
MRSN vs ICG Comparison
Compare MRSN & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- ICG
- Stock Information
- Founded
- MRSN 2001
- ICG 2017
- Country
- MRSN United States
- ICG China
- Employees
- MRSN N/A
- ICG N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- ICG Semiconductors
- Sector
- MRSN Health Care
- ICG Technology
- Exchange
- MRSN Nasdaq
- ICG Nasdaq
- Market Cap
- MRSN 252.0M
- ICG 256.8M
- IPO Year
- MRSN 2017
- ICG 2023
- Fundamental
- Price
- MRSN $1.83
- ICG $4.70
- Analyst Decision
- MRSN Buy
- ICG Strong Buy
- Analyst Count
- MRSN 6
- ICG 1
- Target Price
- MRSN $6.00
- ICG $11.00
- AVG Volume (30 Days)
- MRSN 1.1M
- ICG 88.1K
- Earning Date
- MRSN 11-13-2024
- ICG 11-20-2024
- Dividend Yield
- MRSN N/A
- ICG N/A
- EPS Growth
- MRSN N/A
- ICG N/A
- EPS
- MRSN N/A
- ICG 0.11
- Revenue
- MRSN $34,837,000.00
- ICG $34,648,799.00
- Revenue This Year
- MRSN N/A
- ICG N/A
- Revenue Next Year
- MRSN N/A
- ICG $60.43
- P/E Ratio
- MRSN N/A
- ICG $44.85
- Revenue Growth
- MRSN N/A
- ICG 202.16
- 52 Week Low
- MRSN $1.22
- ICG $3.21
- 52 Week High
- MRSN $6.28
- ICG $14.22
- Technical
- Relative Strength Index (RSI)
- MRSN 42.16
- ICG 49.11
- Support Level
- MRSN $1.93
- ICG $4.70
- Resistance Level
- MRSN $2.81
- ICG $5.12
- Average True Range (ATR)
- MRSN 0.24
- ICG 0.51
- MACD
- MRSN -0.05
- ICG -0.02
- Stochastic Oscillator
- MRSN 7.79
- ICG 32.89
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.